Yazar "Oz Puyan, Fulya" seçeneğine göre listele

Listeleniyor 1 - 3 / 3
  • Küçük Resim Yok
    Öğe
    BRAF V600 Mutation Profile of Metastatic Melanoma in the Thrace Region of Turkey
    (De Gruyter Poland Sp Zoo, 2018) Can, Nuray; Tastekin, Ebru; Deniz Yalta, Tulin; Sut, Necdet; Korkmaz, Selma; Usta, Ufuk; Oz Puyan, Fulya
    Objective: BRAF is the most common mutation in melanoma. The most common subtype is BRAF V600E, followed by V600K. Initially, the authors aimed to investigate whether clinicopathological features of melanoma are associated with BRAF mutations. We then aimed to present the relationships between the clinicopathological features and the mutated subtype (V600E vs V600K). Material and Method: 61 patients with metastatic malignant melanoma (affecting the lymph node or other distant sites) were selected. Patient data regarding age at the time of diagnosis, sex, metastatic site (lymph node, distant metastasis or both) and primary tumour site were obtained from the hospital's database. Tissue samples containing at least 30% tumour cells were isolated from the specimens of 61 patients (24 samples from primary tumours and 37 from metastatic foci) for BRAF analysis. Comparisons between the BRAF V600 mutation and clinicopathological and histopathological features were performed. Results: BRAF V600 mutation was detected in 34 (55.7%) patients. The subtype was BRAF V600E in 22 (64.7%) patients, BRAF V600K in 11(32.4%) patients and BRAF V600R in 1(2.9%) patient. The crucial results of the present study may be summarized as follows: i) BRAF V600 mutation was more common in older patients and tumors with BRAF V600 mutation revealed necrosis and LVI more commonly than wild-type tumors, ii) BRAF V600K mutation was more common in older patients and BRAF V600K mutated tumors exhibited ulceration more commonly than tumors with BRAF V600E mutation (close to significant). Conclusion: The BRAF V600 mutation may have interactions with prognostic clinicoptahological features of melanoma including necrosis and lymphovascular invasion. V600K mutation may be more common than expected and may have different associations with properties of the tumor such as tumor ulceration and patient age. Investigation of the mutated subtype of the BRAF gene may therefore reveal more detailed data about the management of melanoma and may also prevent missing of candidates for BRAF inhibitor therapies.
  • Küçük Resim Yok
    Öğe
    Primary bilateral breast lymphoma in an elder male patient
    (Wiley, 2019) Bozkaya, Yakup; Oz Puyan, Fulya; Bimboga, Busem
    [Abstract Not Available]
  • Küçük Resim Yok
    Öğe
    Prognostic Value of Angiogenesis and Survivin Expression in Patients with Glioblastoma
    (Turkish Neurosurgical Soc, 2016) Tastekin, Ebru; Caloglu, Vuslat Yurut; Oz Puyan, Fulya; Tokuc, Burcu; Caloglu, Murat; Yalta, Tulin Deniz; Can, Nuray
    AIM: Glioblastoma (GBM) is the most common and the most aggressive primary brain tumor with poor prognosis. We aimed to evaluate the association between immunohistochemical expression of survivin and angiogenic parameters (microvessel density and vascular pattern) in patients who underwent surgery for GBM. MATERIAL and METHODS: The pathology reports and also clinical and follow-up data of patients with GBM were retrospectively evaluated. Control tissues were obtained from the archive for each antibody (Survivin, CD 34). Then, control staining of these antibodies was performed. Vessels were evaluated according to the standardized assessment of vascular pattern. RESULTS: Mean survival for classical vascular pattern was longer than bizarre vascular pattern (p<0.001). The survival time of patients decreased with increasing score of survivin staining. There was a significant correlation between survivin and survival time (p<0.001). There was no significant correlation between microvessel density and survival time (p>0.05). CONCLUSION: With these findings, it is considered that high expression of survivin, bizarre vascular pattern and development of secondary GBM correlates with the low survival rates, however microvessel density has no correlation with the survival rates. Since only malignant cells express survivin, it might be a target protein for the development of novel therapies.